加载中
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
收盘时
US$3.96
−US$0.06 · -1.49%
盘后
US$3.96
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
日内区间
当前US$3.96
52周区间
当前US$3.96
盘中时间采用ET。市场数据可能有所延迟。
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
日内区间
当前US$3.96
52周区间
当前US$3.96
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 368.6万 USD | 345.4万 USD | — | — | — |
| 毛利 | −368.6万 USD | −345.4万 USD | — | — | — |
| 研究与开发 | 1.85亿 USD | 1.19亿 USD | 1.14亿 USD | 1.13亿 USD | 1亿 USD |
| 销售、一般及管理费用 | 3170.9万 USD | 3462.5万 USD | 2802.1万 USD | 3094.6万 USD | 3064.7万 USD |
| 营业费用 | 2.13亿 USD | 1.51亿 USD | 1.44亿 USD | 1.46亿 USD | 1.31亿 USD |
| 利息收入 | 971.7万 USD | 1587.3万 USD | 948.6万 USD | 365.2万 USD | 39万 USD |
| 折旧和摊销 | 216.6万 USD | 215万 USD | 214.8万 USD | 210.6万 USD | 214.1万 USD |
| 营业利润 | −2.16亿 USD | −1.54亿 USD | −1.44亿 USD | −1.46亿 USD | −1.31亿 USD |
| 净利润 | −2.07亿 USD | −1.38亿 USD | −1.34亿 USD | −1.42亿 USD | −1.3亿 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2455.49万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2314.42万0.23%98.74亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1655.15万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF876.78万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO584.86万0.04%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB513.53万0.05%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO441.09万0.02%180亿 USD0.06%US$112.27-0.35%
Fidelity Enhanced Small Cap ETFFESM433.64万0.07%64.1亿 USD0.28%US$45.24-0.48%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
